Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307984 | 0.89 | TP53 (0.34) | KMT2AACE2MEN1ALDH1A1 | |
| SCHEMBL1785086 | 0.81 | HDAC2 (0.41) | ACE2CNR1CYP1A2ALDH1A1CARM1 | |
| SCHEMBL3948277 | 0.79 | SLC2A1 (0.38) | ACE2CYP2C19ALDH1A1CARM1PRMT6 | |
| SCHEMBL12465581 | 0.79 | ACE2 (0.48) | KMT2AACE2MEN1CNR1CNR2 | |
| SCHEMBL1307630 | 0.79 | CARM1 (0.50) | ACE2NPC1ALDH1A1CARM1PRMT6 | |
| SCHEMBL5748703 | 0.79 | — | — | |
| SCHEMBL348038 | 0.77 | CARM1 (0.48) | KMT2AMEN1CYP1A2NPC1ALDH1A1 | |
| SCHEMBL10177623 | 0.75 | CARM1 (0.58) | KMT2AMEN1NPC1ALDH1A1CARM1 | |
| SCHEMBL3951607 | 0.75 | SLC2A1 (0.37) | KMT2AACE2MEN1CYP2C19ALDH1A1 | |
| SCHEMBL3949628 | 0.75 | ALDH1A1 (0.43) | KMT2AACE2MEN1CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | KMT2A 2976/4885ACE2 1382/4885MEN1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.